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Abstract
Objective: To determine the key inflammatory pathways that are activated in
the peripheral and CNS compartments at the mild cognitive impairment (MCI)
stage of Alzheimer’s disease (AD). Methods: A cross-sectional study of patients
with clinical and biomarker characteristics consistent with MCI-AD in a discov-
ery cohort, with replication in the Alzheimer’s Disease Neuroimaging Initiative
(ADNI) cohort. Inflammatory analytes were measured in the CSF and plasma
with the same validated multiplex analyte platform in both cohorts and corre-
lated with AD biomarkers (CSF Ab42, total tau (t-tau), phosphorylated tau (p-
tau) to identify key inflammatory pathway activations. The pathways were addi-
tionally validated by evaluating genes related to all analytes in coexpression net-
works of brain tissue transcriptome from an autopsy confirmed AD cohort to
interrogate if the same pathway activations were conserved in the brain tissue
gene modules. Results: Analytes of the tumor necrosis factor (TNF) signaling
pathway (KEGG ID:4668) in the CSF and plasma best correlated with CSF t-
tau and p-tau levels, and analytes of the complement and coagulation pathway
(KEGG ID:4610) best correlated with CSF Ab42 levels. The top inflammatory
signaling pathways of significance were conserved in the peripheral and the
CNS compartments. They were also confirmed to be enriched in AD brain
transcriptome gene clusters. Interpretation: A cell-protective rather than a
proinflammatory analyte profile predominates in the CSF in relation to neu-
rodegeneration markers among MCI-AD patients. Analytes from the TNF sig-
naling and the complement and coagulation pathways are relevant in evaluating
disease severity at the MCI stage of AD.
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Introduction
Alzheimer’s disease (AD) is characterized by a progressive
decline in cognitive function and is the most common
cause of dementia worldwide. Even as classical AD neu-
ropathology is described as amyloid plaques and neu-
rofibrillary tangles in the brain, it is recognized that a
complex cascade of events involving additional molecular
players likely play a crucial role in the disease onset and
progression.
Accumulating evidence implicates inflammatory
changes in AD.1–3 The role of systemic inflammation and
occurrence of amyloid plaque-dependent inflammation
have been well documented in both human autopsy spec-
imens and animal models.4,5 Altered expression of multi-
ple cytokines and chemokines in AD patients compared
to controls have been reported.3,6–10 Alterations in sys-
temic inflammation, including plasma levels of tumor
necrosis factor (TNF)-a-related cytokines have been
linked to worsened cognition in AD.3,10,11 In addition,
genome-wide association studies have demonstrated that
polymorphisms in several inflammatory genes are associ-
ated with modestly increased risk for AD.12,13 A role for
inflammation and immune mechanisms in AD therefore
appears highly likely.14,15
In spite of recognition of the role for inflammation in
the pathophysiology of AD, there are some key outstand-
ing questions. (1) Which key inflammatory pathways are
activated in clinical AD? Among most prior studies of
inflammatory changes in AD patients, small number of
inflammatory analytes were measured, typically 10 or
fewer.6,10,11,16–18 To help identify inflammatory pathways
or networks of inflammatory analytes pertinent to AD and
to evaluate if they are helpful or harmful to cognition, it is
essential to develop approaches that evaluate multiple ana-
lytes concomitantly and interrogate their biological signifi-
cance when expressed together, (2) Prior studies have
predominantly focused on the peripheral compartment
and it remains unclear how the inflammatory changes in
the CNS relates to changes in the peripheral compartment
for a large set of inflammatory molecules. This knowledge
is critical to a mechanistic understanding of the patho-
physiological changes related to inflammation in the
peripheral and CNS compartments simultaneously and to
potentially evaluate the utility of monitoring these inflam-
matory changes in AD for clinical outcomes.
We therefore took a systematic approach to answer
these two questions among mild cognitive impairment
(MCI)-AD clinical patients. After evaluation in our dis-
covery cohort we validated the results among MCI
patients in the Alzheimer’s Disease Neuroimaging Initia-
tive (ADNI) cohort. We also determined if the genes
related to soluble inflammatory analytes evaluated in our
discovery cohort have also been transcribed in the brain
tissue, using transcriptomic data from autopsied AD
brains. Using functional network enrichment analysis we
determined the biological pathways most likely related to
the inflammatory analytes and genes of significance and
its potential convergence across multiple datasets of brain,
CSF, and plasma in the presence of markers of AD
pathology.
Materials and Methods
Discovery cohort
A cross-sectional discovery study of 48 MCI-AD patients
was conducted. All patient consent was obtained accord-
ing to the Declaration of Helsinki and the study was
approved by the Cleveland Clinic Institutional Review
Board. The patients were recruited from a specialized
memory clinic. The diagnosis of MCI-AD was confirmed
by the presence of CSF Ab42 and p-tau levels consistent
with a diagnosis of AD and consensus evaluation of two
neurologists and a neuropsychologist by published crite-
ria.19 A commercially available test from Athena Diagnos-
tics, ADmark Alzheimer’s evaluation Innotest sandwich
Enzyme Linked Immunosorbant Assay (ELISA) kits was
used for measuring CSF levels of Ab42, t-tau, and p-tau
levels. The subjects met cut offs CSF Ab42 ≤ 530pg/mL,
CSF p-tau ≥ 60pg/mL which are consistent with Amyloid
positive status on the Amyvid TM PET at our center. An
additional marker of neuronal degeneration in the CSF,
neuron-specific enolase (NSE), was measured in the rules-
based-medicine (RBM) multiplex analyte platform
described below. NSE is often highly elevated in diseases
which result in relative rapid neuronal destruction
(hours/days) and levels are therefore supportive of a more
recent neuronal loss in relation to analytes measured.
APOE status was determined by blood samples (10 ng per
subject) dispensed into 96 well plates for TaqMan allelic
discrimination detection of single-nucleotide polymor-
phisms that discriminate the APOE alleles (rs429358,
rs7412) (Life Technologies). PCR reactions were carried
out using a 9700 Gene Amp PCR system (Applied Biosys-
tems, CA) and an end-point read in a 7500 Real-Time
PCR system (Applied Biosystems, CA). Table 1 provides
data on discovery cohort demographics and Figure 1 pro-
vides a methodological overview of the study.
Characterizing clinical and environmental
factors
Age, sex, education, medical comorbidities family history,
smoking, and other addictions and medication use,
including nonsteroidal anti-inflammatory drugs (NSAIDs)
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were characterized. Confounding treatment with steroids,
trauma, and surgical intervention and infectious disease
in the last 6 months, in addition to uncontrolled diabetes
and vascular disease as part of clinical evaluation were
screened. Additional preexisting proinflammatory disor-
ders (e.g., systemic lupus erythematosus) were recorded
and levels of C-reactive protein (CRP) and sedimentation
rate related to systemic inflammation was quantified in
the blood. Table S1.
Neuropsychological tests
Mini-Mental State Examination (MMSE),20 WMS-IV
Logical Memory 1 and 2,21 Clinical Dementia Rating scale
(CDR-SB and Global),22 and Dementia Rating Scale
(DRS)23 tests were conducted to characterize the degree
of their baseline cognitive and functional deficits.
Inflammatory biomarkers
CSF and plasma were collected and analyzed by an inde-
pendent laboratory via the validated RBM Multi-Analyte
Profile (MAP) platform from Myriad Genetics (Salt Lake
City, UT). Samples were evaluated for levels of 86 ana-
lytes using a custom MAP: HumanMAP v2.0 + IL1 and
16 using a Luminex platform. Validation has been per-
formed as defined by the Clinical and Laboratory Stan-
dards Institute and is therefore replicable across multiple
runs. CSF and plasma samples were collected contempo-
raneously. They were both frozen within 15 min after
Table 1. Demographics and medical history of Discovery and ADNI cohorts.
Factor
Discovery cohort (N = 48) ADNI cohort (N = 43)
P-valuen Statistics n Statistics
Age at enrollment 48 68.1  7.3 43 76.1  6.5 <0.001a
Gender 48 43 0.11c
Male 28 (58.3) 32 (74.4)
Female 20 (41.7) 11 (25.6)
Years of education 48 16.0 [12.5, 18.0] 43 16.0 [15.0, 18.0] 0.12b
APOEe4 positive 48 37 (77.1) 43 21 (48.8) 0.005c
MMSE 48 24.8  3.1 43 26.6  1.6 <0.001a
CDR-SB 48 2.2  1.3 43 1.5  0.79 0.003a
DRS 47 125.6  10.3 NA
CSF Ab42, pg/mL 48 305.9 [216.1, 367.1] 43 144.0 [135.0, 167.0] <0.001b
CSF t-tau, pg/mL 48 454.3 [335.1, 771.] 43 91.0 [64.0, 132.0] <0.001b
CSF p-tau, pg/mL 48 79.6 [59.3, 104.6] 43 33.0 [21.0, 42.0] <0.001b
Statistics presented as Mean  SD, Median [P25, P75] or N (column %).
P-values: a = ANOVA, b = Kruskal–Wallis test, c = Pearson’s chi-square test.
MMSE, Mini-mental state exam; CDR-SB, Clinical dementia rating scale-sum of boxes.
DRS, Dementia rating scale. P values in bold meet statistical significance <0.05.
Figure 1. Methodological overview.
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collection and processed (at 70°C in dry ice) and main-
tained at a freezing temperature (80°C at a maximum
nonfrost-free type refrigerator) continuously. The samples
were shipped frozen, in a Styrofoam container with suffi-
cient dry ice to maintain temperature less than 70°C for
at least 48 h. Samples therefore underwent a single freeze
thaw cycle prior to analyses. Each analyte measure had to
pass a threshold of measurement and quality control cri-
teria set by Myriad Genetics.
The consistency of the data was further evaluated by
internal and external validation. There were two technical
replicates of CSF and plasma samples chosen randomly
from three patients to evaluate consistency of data.
Expected high degree of correlation within individual sub-
jects analyte profiles between markers of positive acute
phase response (CRP, haptoglobin, ferritin, a2 macroglob-
ulin, fibrinogen) was further confirmed and the results
from the discovery cohort were next evaluated in ADNI.
ADNI validation cohort
ADNI is a longitudinal multicenter study designed to
develop clinical, imaging, genetic, and biochemical
biomarkers for the early detection and tracking of AD.
ADNI was launched by the National Institute of Aging and
is a multicenter project with additional support from private
pharmaceutical companies, and nonprofit organizations.
ADNI 1 eligibility criteria are described in the ADNI 1 pro-
tocol http://adni.loni.usc.edu/methods/documents/. Briefly,
participants are 55–90 years of age, had an informant able to
provide an independent evaluation of functioning, and
spoke either English or Spanish. Participants had completed
at least 6 years of education (or had a work history sufficient
to exclude mental retardation). General inclusion/exclusion
criteria for MCI subjects are as follows: MMSE scores
between 24 and 30 (inclusive; exceptions made on a case by
case basis by neurologists at the center of follow up), a mem-
ory complaint, objective memory loss measured by educa-
tion adjusted scores on Wechsler Memory Scale Logical
Memory II, a CDR of 0.5, absence of significant levels of
impairment in other cognitive domains, essentially pre-
served activities of daily living, and an absence of dementia.
The demographics at baseline among the subset of all
43 ADNI MCI participants who had CSF and plasma
multiplex data were used in the validation analysis are
shown in Table 1. These subjects were noted to have CSF
Ab42, t-tau, and p-tau levels supportive of underlying AD
pathology.24 Details on the Luminex method used for
ADNI AD biomarkers measurement are detailed else-
where.25 CSF samples were measured for levels of 159
analytes using the RBM DiscoveryMAP v.1.0 panel. The
RBM HumanMAP v.2.0 used in the discovery cohort is
a subset of the RBM DiscoveryMAP v.1.0 and uses a
Luminex platform with the same quality control and
thresholding process used in ADNI dataset and are com-
parable. We analyzed data from ADNI’s well-characterized
subset of MCI participants who had curated CSF and
plasma multiplex data, the details of which have been
published previously.26 The data from CSF QC multiplex
data used in this analysis is the cleaned, quality controlled
data according to methodology described in the statistical
analysis of Biomarkers Consortium data primer.27
Bioinformatics and statistical analysis
Ontology analysis and network analysis to
identify inflammatory analytes
Gene/protein annotations and gene ontologies were
downloaded from the Gene Ontology (GO)28 and pro-
cessed into tabular files containing GO terms annotated
to genes and the gene ontology tree. The RBM analyte
names were mapped to HUGO Gene Nomenclature Com-
mittee gene symbols by manual curation. All analytes had
a one to one correspondence with coding genes with the
exceptions of ferritin (heavy chain coding gene FTH1),
and fibrinogen (alpha chain coding gene FGA). The full
ontology tree rooted at the inflammatory response node
(GO:0006954) was constructed and all genes labeled by
this term were extracted (n = 458). The analytes identi-
fied in the proprietary RBM InflammationMAP v1.0
(n = 45 analytes) and the inflammatory response genes
from GO analysis were combined (n = 483) and used in
a network analysis to identify additional analytes from the
RBM HumanMAP v2.0 that are related to inflammation.
The Crosstalker algorithm was run using the 483 seeds to
rank the RBM HumanMAP by their proximity to the
seeds.29,30 The analysis was run using three reference net-
works (STRINGv10.5, BioGRIDv3.4.163, and Human
Protein Reference Database, all latest versions), and
repeated three times on each network since the algorithm
is nondeterministic.21,31 For a target analyte to be deemed
significant it had to pass the significance threshold in all
three runs for the same reference network where signifi-
cance was set at P < 0.2 (z> 0.85). This identified an
additional eight analytes from the RBM HumanMAP
that were combined with the RBM InflammationMAP
(n = 45 analytes) to form our final comprehensive list of
53 candidate inflammatory analytes. The list of inflamma-
tory analytes analyzed in the study is provided in Table 2.
Statistical analysis
The CSF and plasma analytes of interest identified above
were log transformed, which limits the impact of extreme
measures. Only those with at least 50% response rate of
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analytes above the limit of detection were included for fur-
ther analysis Figure S1. The absolute values of the inflam-
matory markers and AD biomarkers were compared.
Normality of biomarkers was evaluated using graphical
methods and the Shapiro–Wilk test and a log (base 2)
transformation allowed Pearson correlations to be fit.
Along with estimates of correlation, 95% confidence inter-
vals and P-values with and without false discovery rate
(FDR) adjustment were calculated. If we assume 53 ana-
lytes (corresponding to a Bonferroni adjusted significance
level of 0.009), with 48 CSF samples and 46 plasma sam-
ples used in each analysis, there would be 80% power to
detect correlations above 0.5 as statistically significant.
Analysis was performed unadjusted and then adjusting for
age, sex, baseline MMSE, and APOEe4 status (present vs.
absent). Agreement on relative ordering of response of
analytes between the discovery and ADNI data was evalu-
ated using Kendall’s W coefficient of concordance statistic.
95% confidence intervals for kappa statistics and P-values
testing whether more agreement than expected by chance
were calculated for both measures. Analysis was performed
using SAS software (version 9.4) and an overall signifi-
cance level of 0.05 was assumed for all tests.
Subgroup searching for analyte synergistic
relationships
In order to evaluate analyte levels that show higher corre-
lation when considered together (synergistic relationship)
rather than individual analyte correlation by univariate
analysis alone, we performed an exhaustive search to find
analyte subgroups whose aggregate levels maximally cor-
related with AD CSF biomarkers. The full panel of ana-
lytes was filtered to contain only those which were
detected in at least 50% of the data. All subgroups of ana-
lytes were enumerated up to maximum group size of six
analytes. Aggregate activity of each subgroup was com-
puted by first normalizing each analyte by subtracting the
mean and dividing by the standard deviation, and then
summing normalized analyte levels for each patient.32,33
The Pearson correlation coefficient was computed
between the aggregate activity of each analyte group and
all response markers (e.g., t-tau levels). Only the highest
scoring analyte subgroup was reported for each response
marker in CSF and plasma, respectively. Significance P-
values for findings were estimated by two tests using an
approach that has been previously described.32 Hypothesis
1(H1) tested how likely we were to see greater or equal
correlation with random analyte subgroups by sampling
10,000 random analyte subgroups (of the same size as
each actual best scoring analyte subgroup) from among
all analytes that met the 50% detection threshold (i.e.,
not just the inflammatory analytes) and computing the
correlation values. P-values were estimated as the fraction
of random subgroups that achieved greater or equal cor-
relation with the response marker as the actual analyte
subgroup. Hypothesis 2(H2) tested how likely we were to
randomly observe greater or equal correlation between
the aggregate activity of an analyte subgroup and a
response marker by permuting the values of each
response marker 10,000 times and computing the correla-
tion values to the aggregate analyte levels. P-values were
estimated as the proportion of randomized responses with
equal or greater correlation with aggregate analyte levels
than the actual response.
Functional pathway analysis on analytes of
interest
The analytes of significance identified in the univariate
statistical analysis and confirmed in the analyte subgroup
search above in relation to CSF neurodegeneration mark-
ers were entered into STRING: functional protein associa-
tion networks for pathway enrichment analysis.34 The top
pathway for each analysis with the largest gene count and
the lowest P value following FDR correction is reported.
Weighted gene coexpression network
analysis (WGCNA) in autopsy AD brains
The R package WGCNA35 was used to construct coex-
pression networks as in prior studies36 using Alzheimer’s
Disease Dataset: GSE 48350 (https://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?acc=GSE48350). Here, postmortem
brain tissue had been collected from ADRC brain banks,
data from all 19 AD brains in the dataset with hippocam-
pal, entorhinal cortex, and superior frontal cortex tran-
scriptomic data were used for the current analysis. The
GSE48350 expression data were reduced to probe sets
corresponding to the 84 RBM full panel genes. Four
HumanMAP RBM analytes were not represented by any
probe sets (IL12, IgE, Chorionic Gonadotropin Subunit
Beta 3, and CA-19-9). The remaining 80 RBM analytes
were represented by 198 probe sets. The modules with
one or more inflammatory analyte genes of significance
shared with plasma or CSF were characterized using GO
Elite to control the network-wide false discovery rate,
with all enriched pathways comprising at least 10 genes at
Z > 2 and FDR < 0.01.37 The gene modules were charac-
terized for their functional enrichment of biological path-
ways using STRING34 to evaluate their functional role.
Results
Subject demographics of the discovery and ADNI cohorts
are in Table 1. Summary statistics of the 53 inflammatory
ª 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. 5
J. A. Pillai et al. Inflammatory Pathways in Alzheimer’s Disease
analytes evaluated in CSF and plasma are provided in
Table S2.
Discovery cohort
Univariate analysis CSF
In the unadjusted analyses, after applying the FDR correc-
tion, TNFR2, SCF, Ferritin, and a2macroglobulin were
positively correlated with CSF t-tau, p-tau, and NSE.
After adjusting for covariates (age, sex, baseline MMSE,
APOEe4 status), the same associations were significant. In
addition, MMP2, MMP3, b2 microglobulin, VCAM1, and
VEGF were positively correlated with CSF t-tau, and p-
tau but not NSE. After adjustment for the same covariates
in addition to the above five analytes, CCL2 (MCP1) and
vWF were also found to be significantly correlated with
CSF t-tau and p-tau. (Table 3). There were no significant
correlations of the CSF inflammatory analytes to CSF
Ab42.
Univariate analysis plasma
In unadjusted analysis after applying the FDR correction,
only a2-macroglobulin was positively correlated with CSF
t-tau and p-tau measures and MMP9 was positively cor-
related with CSF NSE. After adjustment for covariates,
the associations between a2-macroglobulin and CSF p-tau
and between MMP9 and CSF NSE remained significant
(Table 4). There were no significant correlations of the
plasma inflammatory analytes to CSF Ab42.
Secondary analyses
None of the CSF and plasma inflammatory analytes
had a significant degree of correlation with any of the
cognitive measures after applying the FDR correction.
No difference was noted in the analytes of significance
when adjusted for NSAID exposure. Adjusting for indi-
vidual CSF/plasma albumin ratio noted no decrease in
the number of analytes of significance on the Pearson
correlations corrected for FDR. While, complement C3
and vWF were the additional analytes from the unad-
justed correlations with CSF t-tau now meeting FDR
correction.
When comparing univariate correlations between
plasma and CSF inflammatory analytes and CSF AD
biomarkers in the discovery cohort, the correlation val-
ues to AD biomarkers for plasma inflammatory analytes
were lower than those for CSF (Tables 3 and 4 and
Table 2. List of inflammatory analytes analyzed.
RBM Name Gene RBM Name Gene
1. Alpha-1-Antitrypsin SERPINA1 27. Interleukin-12 Subunit p40 IL12B
2. Alpha-2-Macroglobulin A2M 28. Interleukin-12 Subunit p70 IL12P70
3. Apolipoprotein A-I APOA1 29. Interleukin-15 IL15
4. Beta-2-Microglobulin B2M 30. Interleukin-17 IL17A
5. Brain-Derived Neurotrophic Factor BDNF 31. Interleukin-18 IL18
6. Complement C3 C3 32. Interleukin-8 CXCL8
7. C-Reactive Protein CRP 33. Interleukin-23 IL23A
8. Eotaxin-1 CCL11 34. Macrophage Inflammatory Protein-1 alpha CCL3
9. Fibrinogen FGA 35. Macrophage Inflammatory Protein-1 beta CCL4
10. Factor VII F7 36. Matrix Metalloproteinase-3 MMP3
11. Ferritin FTH1 37. Matrix Metalloproteinase-9 MMP9
12. Granulocyte-Macrophage Colony-Stimulating Factor CSF2 38. Monocyte Chemotactic Protein 1 CCL2
13. Granulocyte Colony-Stimulating Factor CSF3 39. Matrix Metalloproteinase-2 MMP2
14. Haptoglobin HP 40. Myeloperoxidase MPO
15. Intercellular Adhesion Molecule 1 ICAM1 41. Neuron-Specific Enolase ENO2
16. Interferon gamma IFNG 42. Plasminogen Activator Inhibitor 1 SERPINE1
17. Interleukin-1 alpha IL1A 43. Serotransferrin TF
18. Interleukin-1 beta IL1B 44. Stem Cell Factor SCF
19. Interleukin-1 receptor antagonist IL1RN 45. T-Cell-Specific Protein RANTES CCL5
20. Interleukin-2 IL2 46. Tissue Inhibitor of Metalloproteinases 1 TIMP1
21. Interleukin-3 IL3 47. Tumor Necrosis Factor alpha TNF
22. Interleukin-4 IL4 48. Tumor Necrosis Factor beta LTA
23. Interleukin-5 IL5 49. Tumor Necrosis Factor Receptor 2 TNFRSF1B
24. Interleukin-6 IL6 50. Vascular Cell Adhesion Molecule-1 VCAM1
25. Interleukin-7 IL7 51. Vascular Endothelial Growth Factor VEGFA
26. Interleukin-10 IL10 52. Vitamin D-Binding Protein GC
53. von Willebrand Factor VWF
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Fig. S2). On Synergistic group analysis A2M, CCL2,
ENO2, MMP3, and TNFRSF1B shared significance
between plasma and CSF t-tau, whereas CCL4, HP, and
SERPINA1 shared synergistic correlations with Ab42
(Table 5).
Comparing inflammatory analytes in ADNI
versus the discovery cohort
On univariate comparisons none of the inflammatory
analyte correlations with CSF neurodegeneration markers
Table 3. Significant associations between CSF inflammatory analytes and CSF neurodegenerative markers (adjusted for age, sex, APOEe4, and
MMSE) in discovery cohort.
Factor 1 Factor 2 N Pearson r (95% CI) Raw P-value False discovery rate (FDR) P-value
Ab42 VDBP 47 0.37 (0.08, 0.60) 0.014 0.16
Total Tau TNFR2 48 0.73 (0.55, 0.84) <0.001 <0.001
SCF 48 0.66 (0.44, 0.80) <0.001 <0.001
B2M 47 0.62 (0.38, 0.77) <0.001 <0.001
Ferritin 48 0.58 (0.33, 0.74) <0.001 <0.001
A2M 48 0.50 (0.24, 0.69) <0.001 0.002
MMP3 48 0.49 (0.22, 0.69) <0.001 0.002
VCAM1 48 0.46 (0.18, 0.66) 0.002 0.012
VEGF 48 0.42 (01.4, 0.64) 0.004 0.012
CCL2 (MCP1) 48 0.38 (0.09, 0.61) 0.009 0.023
vWF 48 0.34 (0.05, 0.58) 0.022 0.047
PhosphoTau TNFR2 48 0.72 (0.54, 0.84) <0.001 <0.001
SCF 48 0.71 (0.52, 0.83) <0.001 <0.001
B2M 47 0.60 (0.36, 0.76) <0.001 <0.001
Ferritin 48 0.59 (0.35, 0.75) <0.001 <0.001
A2M 48 0.57 (0.32, 0.74) <0.001 0.002
VCAM1 48 0.48 (0.21, 0.68) <0.001 0.003
MMP3 48 0.46 (0.18, 0.66) 0.002 0.006
VEGF 48 0.43 (0.14, 0.64) 0.003 0.009
vWF 48 0.41 (0.12, 0.63) 0.005 0.013
CCL2 (MCP1) 48 0.35 (0.05, 0.58) 0.020 0.045
NSE Ferritin 48 0.75 (0.58, 0.85) <0.001 <0.001
SCF 48 0.71 (0.51, 0.83) <0.001 <0.001
TNFR2 48 0.68 (0.47, 0.81) <0.001 <0.001
CCL4 (M1P1b) 48 0.48 (0.21, 0.68) <0.001 0.004
vWF 48 0.48 (0.21, 0.68) <0.001 0.005
A2M 48 0.46 (0.18, 0.66) 0.002 0.008
MMP2 47 0.39 (0.10, 0.62) 0.009 0.036
VCAM1 48 0.36 (0.06, 0.59) 0.017 0.045
MMP3 48 0.31 (0.01, 0.55) 0.043 0.10
AAT 47 0.36 (0.60, 0.07) 0.016 0.045
FDR P values in bold meet statistical significance < 0.05.
Table 4. Significant associations between Plasma inflammatory analytes and CSF neurodegenerative markers (adjusted for age, sex, APOEe4, and
MMSE) in discovery cohort.
Factor 1 Factor 2 N Pearson r (95% CI) Unadjusted P-value False discovery rate (FDR) P-value
ABeta42 CCL4 46 0.39 (0.09, 0.61) 0.011 0.35
AAT 46 0.31 (0.01, 0.56) 0.042 0.41
Total Tau A2M 46 0.38 (0.08, 0.61) 0.013 0.20
ICAM1 45 0.40 (0.63, 0.10) 0.009 0.20
PhosphoTau A2M 46 0.49 (0.22, 0.69) <0.001 0.023
ICAM1 45 0.36 (0.60, 0.05) 0.020 0.31
VEGF 45 0.43 (0.65, 0.13) 0.005 0.10
NSE MMP9 45 0.57 (0.31, 0.74) <0.001 0.002
Haptoglobin 46 0.39 (0.62, 0.09) 0.010 0.16
FDR P values in bold meet statistical significance < 0.05.
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within the ADNI dataset met P < 0.05 FDR correction
threshold. However, most inflammatory analytes shared
similar direction and similar relative ordering/ranking of
correlation distances between ADNI and discovery data
(Fig. 2). Comparing ADNI and the discovery cohorts, the
ordering of the correlations between CSF inflammatory
analytes and neurodegeneration markers was significantly
higher than chance in relation to CSF t-tau and p-tau
(mean diff in correlation: 0.32, W statistic 0.92, P = 0.013
for t-tau). On average, the correlations between the
cohorts were 0.3 or higher in the discovery cohort. The
correlation distances between the two cohorts were lower
for measures in relation CSF Ab42 (mean diff in correla-
tion: 0.11, W statistic 0.64, P = 0.19 for Ab42) and
plasma inflammatory analytes (t-tau, Ab42: mean diff in
correlation: 0.01, 0.03, Wstatistic 0.55, 0.43, P = 0.33,
0.68) (Table S3, Fig. S3).
Analyte subgroup analysis for synergestic
relationships in discovery and ADNI cohorts
On evaluating analyte levels that show higher correlation
when considered together rather than the individual com-
ponent analytes (synergistic analyte analysis), the results
replicated the significant results of univariate Pearson cor-
relations above. In addition it identified groups of ana-
lytes that did not meet statistical significance when
considered alone. The analyte subgroups that best corre-
lated with t-tau, p-tau, and NSE had analytes cross repre-
sented between them and differed from the analyte
subgroup that best correlated with Ab42 in both the CSF
and plasma (Table 5). The synergistic analytes in the dis-
covery cohort that correlated with t-tau that were noted
in both plasma and CSF included a-2 Macroglobulin,
CCL2, NSE(ENO2), MMP3, and TNFR2 (TNFRS1B).
Haptoglobin and a-1-antitrypsin (SERPINA1), while
CCL4 was best correlated with Ab42 in both plasma and
CSF synergistic analyte analysis. On comparing ADNI and
discovery data subanalyte analysis, they again shared com-
mon analyte groups meeting statistical significance that is
detailed in Table 5 and Table S4.
Functional pathway analysis
When CSF and plasma analytes that positively correlated
with t-tau and p-tau measures from univariate and sub-
anayte analyses were entered into STRING,34 the top hit
among the Kyoto Encyclopedia of Genes and Genomes
Table 5. Analyte subgroup analysis with most significant inflammatory analytes in discovery cohort.
CSF factor (+correlation,
correlation) r
H1 P-
value
H2 P-
value Analyte subgroup Shared with plasma
Shared with ADNI
dataset
Ab42+ 0.69 <0.0001 <0.0001 SERPINA1,CRP,HP,CCL4,ENO2,CCL5,
VEGFA,GC,VWF
CCL4,HP, SERPINA1
Ab42 0.039 0.074 0.40 SERPINE1
t-tau+ 0.917 <0.0001 <0.0001 A2M,CRP,F7,FTH1,MMP3,CCL2,
ENO2,TNFRSF1B,VWF
A2M,CCL2,ENO2,
MMP3,TNFRSF1B
FTH1,MMP3
t-tau  0.148 0.018 0.14 SERPINA1,CRP CRP
p-tau+ 0.963 <0.0001 <0.0001 A2M,F7,FTH1,MMP3,CCL2,ENO2,
TNFRSF1B,VWF
A2M,CCL2,ENO2,
MMP3
FTH1,MMP3
PTAU 0.137 0.069 0.17 SERPINA1
Plasma factor
(+correlation,
correlation) r
H1 P-
value
H2 P-
value Analyte subgroup Shared with CSF
Shared with
ADNI dataset
Ab42+ 0.745 <0.0001 <0.0001 SERPINA1,BDNF,F7,FTH1,HP,CCL4,MMP3 CCL4,HP, SERPINA1 FTH1,HP
Ab42 0.795 <0.0001 <0.0001 C3,IL1RN,IL18,MMP2,MMP9,ENO2,CCL5,
GC
MMP2,MMP9
t-tau+ 0.64 <0.0001 0.0011 A2M,B2M,IL12B,MMP3,CCL2,ENO2,
TNFRSF1B,GC
A2M,CCL2,ENO2,
MMP3,TNFRSF1B
t-tau  0.735 <0.0001 <0.0001 B2M,CCL11,ICAM1,MMP9,SERPINE1,
KITLG,CCL5,VCAM1,VEGFA,GC
B2M,CCL11,
MMP9,SERPINE1
p-tau+ 0.685 <0.0001 0.0003 A2M,B2M,IL12B,CCL4,MMP2, MMP3,
CCL2,ENO2,TIMP1,GC
A2M,CCL2,ENO2,
MMP3
CCL4,MMP2
p-tau  0.71 <0.0001 <0.0001 B2M,CCL11,ICAM1,MMP9,SERPINE1,
KITLG,CCL5,VCAM1,VEGFA,GC
H1 and H2 P values in bold meet statistical significance < 0.05.
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(KEGG) pathways38 in both CSF (gene count 4,
P < 0.0001) and plasma (gene count = 3, P = 0.0021)
was the TNF signaling pathway (KEGG entry: hsa04668).
In relation to Ab42 levels both in the CSF (gene count 3,
P = 0.0012) and plasma (gene count 3, P = 0.0022), the
complement and coagulation cascade (KEGG entry:
hsa04610) was noted consistently among the top KEGG
pathway hits (Table S5).
AD brain transcriptomic analysis
Using autopsy AD brain whole-genome transcriptomic
data, three coexpression modules (M1-M3 see Fig. 3 for
module details) were identified. The modules represent
network gene clusters that share highly similar expression
patterns in the three AD brain regions evaluated. Func-
tional analyses by STRING showed that the transciptomic
gene modules again included key inflammatory pathways
identified in the CSF and plasma analytes that correlated
with AD biomarkers (cytokine–cytokine receptor interac-
tion, complement and coagulation cascade, and TNF sig-
naling pathway) (Fig. S3). The modules share genes with
significant analytes from the synergic group analysis
(Module 1: A2M, SCF, MMP2, F7, FTH1, CRP, and
AAT. Module 2: TNFRSF1B, B2M, TIMP1, ICAM1, Mod-
ule 3: did not enrich to a KEGG cluster).
Discussion
This study clearly demonstrates activation of key shared
inflammatory pathways across the CSF, plasma and brain
tissue in human subjects with AD. In our discovery data-
set, the inflammatory analytes that best correlated with
levels of t-tau, p-tau, and NSE levels were in TNF signal-
ing pathway and those that best correlated to Ab42 were
in the complement and coagulation pathway. These path-
way activations were also noted to be enriched in AD
brain tissue following a transcriptomic gene coexpression
analysis.
Replication of CSF and plasma results in
ADNI
The AD biomarkers shared similar relationships to signifi-
cant inflammatory analytes in both the cohorts (Fig. 2).
The discovery cohort with a larger range of AD biomar-
ker values had consistently larger correlation coefficients
than ADNI. The median and range of CSF Ab42 and t-
Figure 2. Cluster plot noting similar correlation ordering among the inflammatory analytes in ADNI and discovery cohorts, with shared ordering
of analytes more notable in CSF than plasma measures.(Colored points: Pearson correlation coefficients of discovery and ADNI analytes,
Connector lines: difference in correlation values for each analyte compared between the two datasets).
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tau, p-tau were different between ADNI and discovery
cohorts (even though both met MCI-AD criteria) likely
due to different analyte platforms for AD biomarkers.
This likely impacts the correlation strengths between
biomarkers and inflammatory analytes. However, these
differences in absolute correlations did not notably
impact the relative ordering/ranking of analyte correla-
tions between the cohorts.
The relative ordering of the CSF inflammatory analyte
correlations with CSF t-tau and t-tau was significantly
high between the ADNI and discovery cohorts, with
slightly lower correspondence for Ab42 and plasma ana-
lytes. Furthermore, in the synergistic subgroup analysis
after FDR correction, among the analytes with at least
50% of values above the limit of detection in the discov-
ery panel, 30% were replicated in ADNI CSF. The
Figure 3. Network analysis dendrogram showing modules based on the coexpression topological overlap of genes related to inflammatory
analytes and brain transcriptome. Color bars give information on module membership in they hold one or more analytes of significance identified
in CSF and plasma. The table provides the related enrichment for KEGG pathways within these specific inflammation-related gene clusters of
interest and false discovery rate.
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functional analysis of synergistic analytes in ADNI also
independently pointed to shared inflammatory pathway
activations as in the discovery cohort.
The differences in analyte correlation strengths between
the discovery and the ADNI cohorts could be related to
number of potential factors, (1) given the well-known
challenges in standardization of AD biomarker quantifica-
tion and these measurements being undertaken by neces-
sity across different laboratories (Table 1) (2) Differences
in patient recruitment characteristics: a memory clinic
sample of MCI subjects with notable cognitive concerns
in the discovery cohort, versus a longitudinal MCI cohort
in ADNI with slightly lower CDR-SB and higher MMSE
(Table 1). This could be related to an earlier stage of
MCI-AD or potential biases against atypical forms of AD
in ADNI (e.g., frontal variant, logopenic aphasia) c)
Fewer shared correlation trends in the plasma than the
CSF between the two cohorts (Fig. 2), also supports the
possibility that these differences could be related to con-
comitant environmental exposures and/or medical comor-
bidities that were different between the cohorts, that
could potentially have had a stronger effect on the plasma
analyte levels than CSF analytes.
Brain transcriptome replication
Our use of AD brain transcriptome to evaluate the
enrichment of inflammatory pathway activation provides
additional level of confidence in the key inflammation-re-
lated pathways identified. The correspondence in key
inflammatory analyte genes, and inflammatory pathways
between brain, CSF, and plasma (A2M, SCF, MMP2, F7,
FTH1, CRP, AAT, TNFRSF1B, B2M, TIMP1, ICAM1) fol-
lowing these results also provides a starting point for fur-
ther experimental investigation of targeted inflammatory
analytes in the CSF/ plasma knowing that a high degree
of conserved biology exists with the brain.
Key analytes of note
Tumor necrosis factor receptor 2 (TNFR2)
Among the TNF signaling pathway analytes, TNFR2 had
a consistently high correlation value to CSF t-tau, p-tau,
and NSE. TNFR2 is expressed primarily in immune and
endothelial cells. Signaling through TNFR2 activates
inflammatory and prosurvival signaling pathways
through subsequent activation of cellular inhibitor of
apoptosis (cIAPs) and the NF-jB pathway.38 Interest-
ingly, prior reports note a negative correlation between
CSF levels of proinflammatory TNFa and t-tau.39 Unlike
TNFR2, it is notable that TNFa and related proinflam-
matory cytokines IL-6 and IL-1b did not meet the limit
of detection in greater than 50% of subjects in both the
cohorts used in the analysis. Taken together these sug-
gest a cell protective role for the TNFR2 mediated path-
way in MCI-AD. Additional analytes that correlated to
the neurodegeneration markers are known to be part of
the TNF signaling pathways mediating downstream func-
tions including leukocyte recruitment across the blood
brain barrier (CCL2), remodeling of extra cellular matrix
(MMP3), cell adhesion (VCAM1), and vascular effects
(VGEF).38,40
Stem cell factor (SCF)
SCF levels also correlated highly to CSF t-tau and p-tau.
It is a hematopoeitic growth factor that is critically
involved in regulation of blood cell production and mobi-
lization of bone marrow stem cells and cell migration.41
SCF is highly overexpressed by neurons at sites of brain
injury. It has been noted to mediate chemoattractant
activity for neural stem/progenitor cell migration and
thought to play a repair role in models of stroke.42 In the
context of AD it has been reported to be low in the CSF
and plasma of AD patients43 and therapeutic effects of
systemic SCF administration in mice models have shown
promise in reducing amyloid.44
The analytes related to the Complement and Coagula-
tion pathways that were strongly related to CSF Ab42
include a-1-antitrypsin, plasminogen activator inhibitor
(PAI) Type 1, and von Willebrand factor in the CSF and
a-1-antitrypsin, complement factor 3 and coagulation fac-
tor VII in the plasma. The main consequences of the acti-
vation of this pathway are the opsonization of pathogens,
the recruitment of inflammatory and immunocompetent
cells, and the direct killing of pathogens.38 The association
between levels of these analytes and Ab burden has been
noted in multiple previous studies.45–48 Among the other
inflammatory analytes of significance in our results, the
relationships between AD diagnosis and CCL2,11
MMP2,49 and VGEF50 have been previously reported,
whereas VCAM1 has been reported in relation to both
AD and vascular cognitive impairment.51
Even as TNF-a, IL-1b, IL-6 and, IL-12 did not meet
threshold for analysis, among proinflammatory cytokines
that met analysis threshold, CSF and plasma CRP had
negative correlations with CSF t-tau in both cohorts,
whereas IL-18 in the plasma had negative correlations
with CSF t-tau in both cohorts (Fig. 2). The direction of
correlation in the above two analytes were consistent
between the ADNI and discovery cohorts. In the plasma,
the lack of some classical proinflammatory analytes as
reported in previous AD meta-analysis, is notable.18 No
prior studies have evaluated inflammatory analytes mea-
sured both in CSF and plasma in relation to CSF AD
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biomarker levels, using Luminex technology to enable
direct comparisons. Additionally as some of the prior
studies lacked data on clinical variables that could impact
proinflammation markers including comorbidities and
concomitant medications (evaluated in this study), that
could also account for difference in results.
Another inference from our CSF data is that, at the
MCI stage of AD, TNF pathway cytokines that have been
noted in AD animal and in vitro models in relation to
amyloid,52 were here best correlated not to CSF Ab42
levels but to CSF t-tau, p-tau, and NSE pointing to
potential TNF pathway activation in relation to beta amy-
loid deposition starting earlier in preclinical AD53 that
warrants investigation.
Strengths and limitations
There are several differences between the current study
design and previous reports. First, even though some
prior reports had a larger number of subjects than this
study, they often lacked characterization by AD biomark-
ers, and often focused on the dementia stage of AD, both
of which could potentially add confounders to the results.
Furthermore, none of these previous studies had a valida-
tion cohort to evaluate replicability of results on the same
analysis platform. Additionally the methods used in prior
analyses were based on in-house methodologies, mostly
ELISA, and not from a clinically validated shared resource
that others could replicate their results against, limiting
the generalizability. Second, there are concomitant CSF
and plasma measurements to evaluate both peripheral
and CNS-related inflammation changes in this report.
Third, this study has multiple internal and external valid-
ity checks to account for quality of data and measure-
ments. Fourth, we were able go beyond single analyte
associations to meaningfully assess multiple analytes and
narrow our focus to key activated biological pathways.
Fifth, we could assess the relevance of functional pathways
identified in CSF and plasma across two different cohorts
and for their activation in the AD brain tissue as well and
validate these results.
Despite these strengths both Type I and II errors
have to be considered in this study where we do not
confirm some plasma analyte results reported previ-
ously, while other analytes (e.g., YKL-40) were not ana-
lyzed in the RBM MAP. Our results pass a stringent
multiple comparisons cut-off but it is possible that with
weaker enrichment patterns other analytes of signifi-
cance may become more salient with increased sample
sizes. Lack of neuropathologic confirmation of diagnosis
also limits our understanding of the role for mixed
pathology.
Conclusion
We report key inflammation-related pathway activations
related to the TNF signaling pathway and complement
and coagulation cascade were conserved in plasma, CSF
and brain tissue in symptomatic AD. A cell protective
rather than the proinflammatory analyte profile predomi-
nates in the CSF at the MCI-stage of AD in relation to
neurodegeneration markers. Exploring their modulation
toward therapeutic outcomes could be of clinical interest.
Acknowledgment
We thank the patients and families who took part in the
discovery cohort at Cleveland Clinic Lou Ruvo Center for
Brain Health.
Data collection and sharing for this project was funded
by the Alzheimer’s Disease Neuroimaging Initiative
(ADNI) (National Institutes of Health Grant U01
AG024904) and DOD ADNI (Department of Defense
award number W81XWH-12-2-0012). ADNI is funded by
the National Institute on Aging, the National Institute of
Biomedical Imaging and Bioengineering, and through
generous contributions from the following: AbbVie, Alz-
heimer’s Association; Alzheimer’s Drug Discovery Foun-
dation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-
Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai
Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company;
EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated
company Genentech, Inc.; Fujirebio; GE Healthcare;
IXICO Ltd.; Janssen Alzheimer Immunotherapy Research
& Development, LLC.; Johnson & Johnson Pharmaceuti-
cal Research & Development LLC.; Lumosity; Lundbeck;
Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; Neu-
roRx Research; Neurotrack Technologies; Novartis Phar-
maceuticals Corporation; Pfizer Inc.; Piramal Imaging;
Servier; Takeda Pharmaceutical Company; and Transition
Therapeutics. The Canadian Institutes of Health Research
is providing funds to support ADNI clinical sites in
Canada. Private sector contributions are facilitated by the
Foundation for the National Institutes of Health (www.f
nih.org). The grantee organization is the Northern Cali-
fornia Institute for Research and Education, and the study
is coordinated by the Alzheimer’s Therapeutic Research
Institute at the University of Southern California. ADNI
data are disseminated by the Laboratory for Neuro Imag-
ing at the University of Southern California.
Author Contributions
1. Research Project: A. Conception, B. Organization, C.
Execution; 2. Statistical Analysis: A. Design, B. Execution,
12 ª 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
Inflammatory Pathways in Alzheimer’s Disease J. A. Pillai et al.
C. Review and Critique; 3. Manuscript Preparation: A.
Writing the First Draft, B. Review and Critique.
J.A.P.: 1) A, B, C 2) A, B 3) A
B.T.L.: 1) A 2) C 3) B
S.M.: 2) A, B 3) B
J.B.: 2) A, B 3) B
L.M.B.: 1) B, 2) C, 3) B
S.M.R.: 1) B, 2) C, 3) B
M.C.: 1) B, 2) C, 3) B
J.B.L.: 1) B, 2) C, 3) B
Conflict of Interest
Full Financial Disclosures of all Authors for the Past Year:
Jagan A Pillai has obtained funding for research from
the National Institutes of Health, Alzheimer’s Association
and Keep Memory Alive foundation. Bruce T Lamb has
received honoraria or consulting fees from Eli Lilly,
Amgen and Eisai and research funding from the National
Institutes of Health, US Department of Defense, the Alz-
heimer’s Association and the BrightFocus Foundation.
Stephen M. Rao has received honoraria, royalties or con-
sulting fees from: Biogen, Genzyme, Novartis, American
Psychological Association, International Neuropsychologi-
cal Society and research funding from the National Insti-
tutes of Health, US Department of Defense, National
Multiple Sclerosis Society, CHDI Foundation, Biogen, and
Novartis. James B. Leverenz has received consulting fees
from Axovant, GE Healthcare, Navidea Biopharmaceuti-
cals, Takeda, and Grant support from Alzheimer’s Associ-
ation, Alzheimer’s Drug Discovery Foundation, Biogen,
Genzyme/Sanofi, Lundbeck, Michael J Fox Foundation,
National Institute of Health. Sean Maxwell, James Bena,
Lynn Bekris, Mark Chance declared no conflict of
interest.
References
1. Wyss-Coray T. Inflammation in Alzheimer disease: driving
force, bystander or beneficial response? Nat Med
2006;12:1005–1015.
2. Holtzman DM, Mandelkow E, Selkoe DJ. Alzheimer
disease in 2020. Cold Spring Harb Perspect Med 2012;1:
a011585.
3. Bettcher BM, Kramer JH. Longitudinal inflammation,
cognitive decline, and Alzheimer’s disease: a mini-review.
Clin Pharmacol Ther 2014;96:464–469.
4. Perry VH, Cunningham C, Holmes C. Systemic infections
and inflammation affect chronic neurodegeneration. Nat
Rev Immunol 2007;7:161–167.
5. Holmes C, Cunningham C, Zotova E, et al. Systemic
inflammation and disease progression in Alzheimer
disease. Neurology 2009;73:768–774.
6. Song F, Poljak A, Smythe GA, Sachdev P. Plasma
biomarkers for mild cognitive impairment and Alzheimer’s
disease. Brain Res Rev 2009;61:69–80.
7. Lucin KM, Wyss-Coray T. Immune activation in brain
aging and neurodegeneration: too much or too little?
Neuron 2009;15:110–122.
8. Craig-Schapiro R, Perrin RJ, Roe CM, et al. YKL-40: a
novel prognostic fluid biomarker for preclinical
Alzheimer’s disease. Biol Psychiatry 2010;15:903–912.
9. Reaux-Le Goazigo A, Van Steenwinckel J, Rostene W et al.
Current status of chemokines in the adult CNS. Prog
Neurogibol 2013;104:67–92.
10. Hye A, Riddoch-Contreras J, Baird AL, et al. Plasma
proteins predict conversion to dementia from prodromal
disease. Alzheimer’s Dement 2014;10:799–807.
11. Westin K, Buchhave P, Nielsen H, et al. CCL2 is
associated with a faster rate of cognitive decline during
early stages of Alzheimer’s disease. PLoS ONE 2012;7:
e30525.
12. Tosto G, Reitz C. Genome-wide association studies in
Alzheimer’s disease: a review. Curr Neurol Neurosci Rep
2013;13:381.
13. Jonsson T, Stefansson H, Steinberg S, et al. Variant of
TREM2 associated with the risk of Alzheimer’s disease. N
Engl J Med 2013;368:107–116.
14. Wyss-Coray T, Rogers J. Inflammation in Alzheimer
disease-a brief review of the basic science and clinical
literature. Cold Spring Harb Perspect Med 2012;2:a006346.
15. Heneka MT, Carson MJ, El Khoury J, et al.
Neuroinflammation in Alzheimer’s disease. Lancet Neurol
2015;14:388–405.
16. Swardfager W, Lancto^t K, Rothenburg L, et al. A meta-
analysis of cytokines in Alzheimer’s disease. Biol
Psychiatry 2010;68:930–941.
17. Saleem M, Herrmann N, Swardfager W, et al.
Inflammatory markers in mild cognitive impairment: a
meta-analysis. J Alzheimers Dis 2015;47:669–679.
18. Lai K, Liu CS, Rau A, et al. Peripheral inflammatory
markers in Alzheimer’s disease: a systematic review and
meta-analysis of 175 studies. J Neurol Neurosurg
Psychiatry 2017;88:876–882.
19. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis
of mild cognitive impairment due to Alzheimer’s disease:
recommendations from the National Institute on Aging-
Alzheimer’s Association workgroups on diagnostic
guidelines for Alzheimer’s disease. Alzheimer’s Dement
2011;7:270–279.
20. Folstein MF, Folstein SE, McHugh PR. "Mini-mental
state". A practical method for grading the cognitive state
of patients for the clinician. J Psychiatr Res 1975;12:189–
198.
21. Wechsler D. Wechsler memory scale—revised. San
Antonio, TX: The Psychological Corporation, 1987.
ª 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. 13
J. A. Pillai et al. Inflammatory Pathways in Alzheimer’s Disease
22. Morris JC. The Clinical Dementia Rating (CDR): current
version and scoring rules. Neurology 1993;43:2412–2414.
23. Mattis S. Dementia rating scale: professional manual.
Odessa, FL: Psychological Assessment Resources, 1988.
24. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al.
Alzheimer’s disease neuroimaging initiative. Cerebrospinal
fluid biomarker signature in Alzheimer’s disease
neuroimaging initiative subjects. Ann Neurol 2009;65:403–
413.
25. Olsson A, Vanderstichele H, Andreasen N, et al.
Simultaneous measurement of beta-amyloid(1–42), total
tau, and phosphorylated tau (Thr181) in cerebrospinal
fluid by the xMAP technology. Clin Chem 2005;51:336–
345.
26. Khan W, Aguilar C, Kiddle SJ, et al. A subset of
cerebrospinal fluid proteins from a multi-analyte panel
associated with brain atrophy, disease classification and
prediction in Alzheimer’s disease. PLoS ONE 2015;10:
e0134368.
27. Biomarkers Consortium ADNI CSF Targeted Proteomics
Project - Data Primer Version 28 Dec 2011. Downloaded
from "http://adni.loni.usc.edu/methods/" on December 1st
2018.
28. The Gene Ontology Consortium. Expansion of the gene
ontology knowledgebase and resources. Nucleic Acids Res
2017;45:D331–D338.
29. Nibbe RK, Koyut€urk M, Chance MR. An integrative -
omics approach to identifyfunctional sub-networks in
human colorectal cancer. PLoS Comput Biol 2010;6:
e1000639.
30. Maxwell S, Chance MR, Koyut€urk M. Linearity of
network proximity measures: implications for set-based
queries and significance testing. Bioinformatics
2017;33:1354–1361.
31. Chatraryamontri A, Oughtred R, Boucher L, et al. The
BioGRID interaction database: 2017 update. Nucleic Acids
Res 2017;45:D369–D379.
32. Nibbe RK, Markowitz S, Myeroff L, et al. Discovery and
scoring of protein interaction subnetworks discriminative
of late stage human colon cancer. Mol Cell Proteomics
2009;8:827–845.
33. Chuang HY, Lee E, Liu YT, et al. Network-based
classification of breast cancer metastasis. Mol Syst Biol
2007;3:140.
34. Szklarczyk D, Morris JH, Cook H, et al. The STRING
database in 2017: quality-controlled protein-protein
association networks, made broadly accessible. Nucleic
Acids Res 2017;45:D362–D368.
35. Langfelder P, Zhang B, Horvath S. Defining clusters from
a hierarchical cluster tree: the Dynamic Tree Cut package
for R. Bioinformatics 2008;24:719–720.
36. Parikshak NN, Luo R, Zhang A, et al. Integrative
functional genomic analyses implicate specific molecular
pathways and circuits in autism. Cell 2013;155:1008–1021.
37. Zambon AC, Gaj S, Ho I, et al. GO-Elite: a flexible
solution for pathway and ontology over-representation.
Bioinformatics 2012;28:2209–2210.
38. Kanehisa M, Sato Y, Kawashima M, et al. KEGG as a
reference resource for gene and protein annotation.
Nucleic Acids Res 2016;44:D457–D462.
39. Tarkowski E, Blennow K, Wallin A, Tarkowski A.
Intracerebral production of tumor necrosis factor-alpha, a
local neuroprotective agent, in Alzheimer disease and
vascular dementia. J Clin Immunol 1999;19:223–230.
40. Lancet D, Safran M, Olender T, et al.GeneCards tools for
combinatorial annotation and dissemination of human
genome information GIACS Conference on Data in
Complex Systems April, 2008. www.genecards.org.
41. Sanchez-Ramos J, Song S, Cao C, Arendash G. The
potential of hematopoietic growth factors for treatment of
Alzheimer’s disease: a mini-review. BMC Neurosci 2008;9
(Suppl 2):S3.
42. Zhao LR, Singhal S, Duan WM, et al. Brain repair by
hematopoietic growth factors in a rat model of stroke.
Stroke 2007;38:2584–2591.
43. Laske C, Stellos K, Stransky E, et al. Decreased plasma and
cerebrospinal fluid levels of stem cell factor in patients
with early Alzheimer’s disease. J Alzheimers Dis
2008;15:451–460.
44. Li B, Gonzalez-Toledo ME, Piao CS, et al. Stem cell factor
and granulocyte colony-stimulating factor reduce b-
amyloid deposits in the brains of APP/PS1 transgenic
mice. Alzheimers Res Ther 2011;3:8.
45. Nilsson LN, Bales KR, DiCarlo G, et al. Alpha-1-
antichymotrypsin promotes beta-sheet amyloid plaque
deposition in a transgenic mouse model of Alzheimer’s
disease. J Neurosci 2001;21:1444–1451.
46. Akhter H, Huang WT, van Groen T, et al. A small
molecule inhibitor of plasminogen activator inhibitor-1
reduces brain amyloid-b Load and improves memory in
an animal model of Alzheimer’s disease. J Alzheimers Dis
2018;64:447–457.
47. Shi Q, Chowdhury S, Ma R, et al. Complement C3
deficiency protects against neurodegeneration in aged
plaque-rich APP/PS1 mice. Sci Transl Med 2017;9:
eaaf6295.
48. Cortes-Canteli M, Zamolodchikov D, Ahn HJ, et al.
Fibrinogen and altered hemostasis in Alzheimer’s disease. J
Alzheimers Dis 2012;32:599–608.
49. Duits FH, Hernandez-Guillamon M, Montaner J, et al.
Matrix metalloproteinases in Alzheimer’s disease and
concurrent cerebral microbleeds. J Alzheimers Dis
2015;48:711–720.
50. Hohman TJ, Bell SP, Jefferson AL. Alzheimer’s disease
neuroimaging initiative. The role of vascular endothelial
growth factor in neurodegeneration and cognitive decline:
exploring interactions with biomarkers of Alzheimer
disease. JAMA Neurol 2015;72:520–529.
14 ª 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
Inflammatory Pathways in Alzheimer’s Disease J. A. Pillai et al.
51. Zuliani G, Cavalieri M, Galvani M, et al. Markers of
endothelial dysfunction in older subjects with late onset
Alzheimer’s disease or vascular dementia. J Neurol Sci
2008;15:164–170.
52. McAlpine FE, Tansey MG. Neuroinflammation and tumor
necrosis factor signaling in the pathophysiology of
Alzheimer’s disease. J Inflamm Res 2008;1:29–39.
53. Sutphen CL, Jasielec MS, Shah AR, et al. Longitudinal
cerebrospinal fluid biomarker changes in preclinical
Alzheimer disease during middle age. JAMA Neurol
2015;72:1029–1042.
Supporting Information
Additional supporting information may be found online
in the Supporting Information section at the end of the
article.
Figure S1. Plot noting analytes that met lower limit of
detection in at least 50% of subjects.
Figure S2. Cluster plot noting correlation coefficients of
inflammatory analytes in plasma and CSF with AD
biomarkers CSF t-tau, p-tau, and Ab42 in the discovery
cohort.
Figure S3. Scatter plot of individual analyte correlations
between ADNI and discovery cohort.
Table S1. Additional clinical and environmental charac-
teristics of the discovery cohort.
Table S2. Summary statistics of analyte markers in
plasma and CSF.
Table S3. Agreement statistics for correlations between
inflammatory analytes and AD biomarkers between ADNI
and discovery cohorts.
Table S4. Analyte subgroup analysis with most significant
inflammatory analytes in the ADNI cohort.
Table S5. Significant KEGG pathways enriched in syner-
getic analyte analysis in discovery cohort.
ª 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. 15
J. A. Pillai et al. Inflammatory Pathways in Alzheimer’s Disease
